Early prophylaxis with recombinant human interleukin-11 prevents spontaneous diabetes in nod mice

Ferdinando Nicoletti, Paola Zaccone, Ignacio Conget, Ramon Gomis, Christer Möller, PierLuigi Meroni, Klaus Bendtzen, William Trepicchio, Stellan Sandler

Research output: Contribution to journalArticle

Abstract

We evaluated the effects of recombinant human (rh) interleukin (IL)-11 on the development of spontaneous and cyclophosphamide-induced diabetes in female NOD mice. Prolonged treatment with rhIL-11 10 μg i.p. five consecutive times a week between the 4th and 22nd weeks of age significantly suppressed both development and cumulative incidence of type 1 diabetes. Disease protection was transient because most of the animals developed type 1 diabetes within 3 months of treatment withdrawal. In contrast, rhIL-11 failed to prevent type 1 diabetes when administered for the first time to euglycemic 18-week-old NOD mice. Most likely, this discrepancy was not due to age- dependent differences in the immunological responses of NOD mice to rhIL-11 because staphylococcus aureus enterotoxin B-induced tumor necrosis factor (TNF) and IL-12 production were equally suppressed by rhIL-11 in 12- and 25- week-old NOD mice. Relative to controls, NOD mice pretreated with rhIL-11 also showed significantly diminished blood levels of TNF, interferon-γ, and IL-12 induced by anti-CD3 antibody and/or lipopolysaccharide. The results demonstrate that rhIL-11 has powerful anti-inflammatory effects that are capable of down-regulating early immunodiabetogenic pathways in NOD mice.

Original languageEnglish
Pages (from-to)2333-2339
Number of pages7
JournalDiabetes
Volume48
Issue number12
Publication statusPublished - Dec 1999

Fingerprint

oprelvekin
Interleukin-11
Inbred NOD Mouse
Type 1 Diabetes Mellitus
Interleukin-12
Tumor Necrosis Factor-alpha
Cyclophosphamide
Interferons
Lipopolysaccharides
Staphylococcus aureus
Anti-Idiotypic Antibodies
Anti-Inflammatory Agents

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Nicoletti, F., Zaccone, P., Conget, I., Gomis, R., Möller, C., Meroni, P., ... Sandler, S. (1999). Early prophylaxis with recombinant human interleukin-11 prevents spontaneous diabetes in nod mice. Diabetes, 48(12), 2333-2339.

Early prophylaxis with recombinant human interleukin-11 prevents spontaneous diabetes in nod mice. / Nicoletti, Ferdinando; Zaccone, Paola; Conget, Ignacio; Gomis, Ramon; Möller, Christer; Meroni, PierLuigi; Bendtzen, Klaus; Trepicchio, William; Sandler, Stellan.

In: Diabetes, Vol. 48, No. 12, 12.1999, p. 2333-2339.

Research output: Contribution to journalArticle

Nicoletti, F, Zaccone, P, Conget, I, Gomis, R, Möller, C, Meroni, P, Bendtzen, K, Trepicchio, W & Sandler, S 1999, 'Early prophylaxis with recombinant human interleukin-11 prevents spontaneous diabetes in nod mice', Diabetes, vol. 48, no. 12, pp. 2333-2339.
Nicoletti F, Zaccone P, Conget I, Gomis R, Möller C, Meroni P et al. Early prophylaxis with recombinant human interleukin-11 prevents spontaneous diabetes in nod mice. Diabetes. 1999 Dec;48(12):2333-2339.
Nicoletti, Ferdinando ; Zaccone, Paola ; Conget, Ignacio ; Gomis, Ramon ; Möller, Christer ; Meroni, PierLuigi ; Bendtzen, Klaus ; Trepicchio, William ; Sandler, Stellan. / Early prophylaxis with recombinant human interleukin-11 prevents spontaneous diabetes in nod mice. In: Diabetes. 1999 ; Vol. 48, No. 12. pp. 2333-2339.
@article{b74e8c6df20a4dafbd4fda5e179e38f0,
title = "Early prophylaxis with recombinant human interleukin-11 prevents spontaneous diabetes in nod mice",
abstract = "We evaluated the effects of recombinant human (rh) interleukin (IL)-11 on the development of spontaneous and cyclophosphamide-induced diabetes in female NOD mice. Prolonged treatment with rhIL-11 10 μg i.p. five consecutive times a week between the 4th and 22nd weeks of age significantly suppressed both development and cumulative incidence of type 1 diabetes. Disease protection was transient because most of the animals developed type 1 diabetes within 3 months of treatment withdrawal. In contrast, rhIL-11 failed to prevent type 1 diabetes when administered for the first time to euglycemic 18-week-old NOD mice. Most likely, this discrepancy was not due to age- dependent differences in the immunological responses of NOD mice to rhIL-11 because staphylococcus aureus enterotoxin B-induced tumor necrosis factor (TNF) and IL-12 production were equally suppressed by rhIL-11 in 12- and 25- week-old NOD mice. Relative to controls, NOD mice pretreated with rhIL-11 also showed significantly diminished blood levels of TNF, interferon-γ, and IL-12 induced by anti-CD3 antibody and/or lipopolysaccharide. The results demonstrate that rhIL-11 has powerful anti-inflammatory effects that are capable of down-regulating early immunodiabetogenic pathways in NOD mice.",
author = "Ferdinando Nicoletti and Paola Zaccone and Ignacio Conget and Ramon Gomis and Christer M{\"o}ller and PierLuigi Meroni and Klaus Bendtzen and William Trepicchio and Stellan Sandler",
year = "1999",
month = "12",
language = "English",
volume = "48",
pages = "2333--2339",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "12",

}

TY - JOUR

T1 - Early prophylaxis with recombinant human interleukin-11 prevents spontaneous diabetes in nod mice

AU - Nicoletti, Ferdinando

AU - Zaccone, Paola

AU - Conget, Ignacio

AU - Gomis, Ramon

AU - Möller, Christer

AU - Meroni, PierLuigi

AU - Bendtzen, Klaus

AU - Trepicchio, William

AU - Sandler, Stellan

PY - 1999/12

Y1 - 1999/12

N2 - We evaluated the effects of recombinant human (rh) interleukin (IL)-11 on the development of spontaneous and cyclophosphamide-induced diabetes in female NOD mice. Prolonged treatment with rhIL-11 10 μg i.p. five consecutive times a week between the 4th and 22nd weeks of age significantly suppressed both development and cumulative incidence of type 1 diabetes. Disease protection was transient because most of the animals developed type 1 diabetes within 3 months of treatment withdrawal. In contrast, rhIL-11 failed to prevent type 1 diabetes when administered for the first time to euglycemic 18-week-old NOD mice. Most likely, this discrepancy was not due to age- dependent differences in the immunological responses of NOD mice to rhIL-11 because staphylococcus aureus enterotoxin B-induced tumor necrosis factor (TNF) and IL-12 production were equally suppressed by rhIL-11 in 12- and 25- week-old NOD mice. Relative to controls, NOD mice pretreated with rhIL-11 also showed significantly diminished blood levels of TNF, interferon-γ, and IL-12 induced by anti-CD3 antibody and/or lipopolysaccharide. The results demonstrate that rhIL-11 has powerful anti-inflammatory effects that are capable of down-regulating early immunodiabetogenic pathways in NOD mice.

AB - We evaluated the effects of recombinant human (rh) interleukin (IL)-11 on the development of spontaneous and cyclophosphamide-induced diabetes in female NOD mice. Prolonged treatment with rhIL-11 10 μg i.p. five consecutive times a week between the 4th and 22nd weeks of age significantly suppressed both development and cumulative incidence of type 1 diabetes. Disease protection was transient because most of the animals developed type 1 diabetes within 3 months of treatment withdrawal. In contrast, rhIL-11 failed to prevent type 1 diabetes when administered for the first time to euglycemic 18-week-old NOD mice. Most likely, this discrepancy was not due to age- dependent differences in the immunological responses of NOD mice to rhIL-11 because staphylococcus aureus enterotoxin B-induced tumor necrosis factor (TNF) and IL-12 production were equally suppressed by rhIL-11 in 12- and 25- week-old NOD mice. Relative to controls, NOD mice pretreated with rhIL-11 also showed significantly diminished blood levels of TNF, interferon-γ, and IL-12 induced by anti-CD3 antibody and/or lipopolysaccharide. The results demonstrate that rhIL-11 has powerful anti-inflammatory effects that are capable of down-regulating early immunodiabetogenic pathways in NOD mice.

UR - http://www.scopus.com/inward/record.url?scp=0033506253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033506253&partnerID=8YFLogxK

M3 - Article

C2 - 10580421

AN - SCOPUS:0033506253

VL - 48

SP - 2333

EP - 2339

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 12

ER -